CClinicalTrials.gg
Active, not recruitingNCT07309705CASSISS-DPRUpdated Dec 30, 2025

Digital Angiography-Derived Fractional Flow Assessment for Intracranial Stenosis

An observational study in Intracranial Atherosclerosis ICAS, Hemodynamic and Stroke, sponsored by Xuanwu Hospital, Beijing. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Xuanwu Hospital, Beijing · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The goal of this observational study is to learn whether a digital angiography derived fractional flow reserve (DPR) measurement can improve the prediction of stroke risk in adults with symptomatic intracranial atherosclerotic stenosis, defined as 50 to 99 percent narrowing.

The main questions it aims to answer are:

Does DPR identify patients who are at higher risk of recurrent stroke despite receiving standard medical treatment? Is DPR more accurate than traditional angiographic stenosis measurements for assessing the functional severity of intracranial arterial disease?

Participants will undergo routine digital subtraction angiography as part of their clinical evaluation. Their angiographic images will be analyzed using a computational method to estimate blood flow impairment, and they will be followed for up to 12 months to monitor stroke related outcomes.

Read the detailed description

Intracranial atherosclerotic stenosis (ICAS) is a major cause of ischemic stroke, representing \~15% of cases in Western populations and up to 46.6% in Asia. Even with intensive medical therapy, annual stroke recurrence remains high (7.2-20%), prompting exploration of additional treatment strategies. Early trials such as SAMMPRIS and VISSIT suggested worse outcomes with stenting compared with aggressive medical therapy, largely due to concerns over operator experience, patient selection, and timing. Subsequent analyses showed that patients with hemodynamic compromise-such as watershed infarction and poor collaterals-have recurrence rates up to 37%, underscoring the central role of impaired cerebral perfusion.

Although more recent studies (CASSISS, BASIS) demonstrated that endovascular therapy may be safe and effective in carefully selected patients, current ICAS assessment relies primarily on stenosis severity, which correlates only weakly with true hemodynamic impairment and is insufficient for accurate risk stratification. Because symptoms arise principally from reduced perfusion, physiologic evaluation is essential.

Fractional flow reserve (FFR) is the gold standard for assessing coronary lesion significance and guiding intervention through translesional pressure gradients. Attempts to translate this approach to ICAS using invasive pressure wires have shown feasibility but remain limited by anatomical differences, lack of dedicated devices, procedural risks, and unclear outcome thresholds.

Our prior work demonstrated that intracranial translesional pressure gradients correlate strongly with cerebral blood flow in both animal models and clinical settings, validating hemodynamic relevance. To overcome the limitations of invasive measurements, the present study seeks to develop and evaluate a noninvasive, angiography-derived pressure ratio (DPR) using routine digital subtraction angiography. This method allows physiologic assessment without pressure wires and may reduce procedural risk.

The objectives of this project are to establish a computational DPR technique, determine its association with clinical outcomes, identify a hemodynamic threshold for stroke-risk stratification, and validate its performance in a prospective multicenter cohort. By enabling early identification of high-risk ICAS patients who may respond poorly to medical therapy, DPR has the potential to improve treatment selection and outcomes, ultimately advancing strategies for stroke prevention.

02

Conditions studied

  • Intracranial Atherosclerosis ICAS
  • Hemodynamic
  • Stroke

Browse trials for

Keywords

  • Intracranial Atherosclerotic Stenosis
  • Recurrent Stroke Risk
  • Hemodynamic Impairment
  • Fractional Flow Reserve
  • Precision Risk Stratification
03

In context

Stroke

7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.

This study's planned enrollment of 400 is above the median of 160 across 1,692 observational studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Xuanwu Hospital, Beijing is the lead sponsor of 346 studies on the registry; 217 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adults aged 18 to 80 years with symptomatic intracranial atherosclerotic stenosis (50%-99%) of a major anterior-circulation artery, who experienced a target-artery-related ischemic event (ischemic stroke involving \<50% MCA territory or TIA) within the past 12 months and are eligible for medical therapy and DPR evaluation.

Inclusion criteria

  1. Patients with intracranial atherosclerotic stenosis (ICAS) of the anterior circulation.
  2. History of an ischemic cerebrovascular event related to the target artery within the past 12 months, including ischemic stroke involving less than one-half of the middle cerebral artery territory or transient ischemic attack.
  3. Age between 18 and 80 years.
  4. Stenosis severity of 50% to 99% identified by transcranial Doppler ultrasound, CT angiography, or MR angiography, and confirmed as 50% to 99% stenosis on digital subtraction angiography.
  5. Good compliance, willingness to sign written informed consent, and ability to complete follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Non-atherosclerotic intracranial stenosis such as moyamoya disease, vasculitis, or arterial dissection.
  2. Coexisting ipsilateral arterial stenosis greater than 50% other than the target lesion.
  3. Large territorial infarction on MRI DWI involving at least one-half of the MCA territory with a modified Rankin Scale score greater than 3.
  4. Contraindications to the use of antiplatelet agents or statins.
  5. Inability to undergo DSA because of severe iodinated contrast allergy, severe hyperthyroidism, severe coagulation abnormalities with high bleeding risk, or severe cardiac, hepatic, or renal insufficiency.
  6. Pregnant or breastfeeding women.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • CASSISS-DPR

    Drug: Standardized medical therapy targeting vascular risk factors and stroke prevention

Interventions

  • DrugStandardized medical therapy targeting vascular risk factors and stroke prevention

    Dual antiplatelet treatment and management of vascular risk factors, in accordance with AHA/ASA guidelines

06

What researchers measure

Primary outcomes

  1. ischemic stroke in the qualifying artery territory or related death within 1 year after enrollment.

    the number of participants who suffer from ischemic stroke in the qualifying artery territory or related death within 1 year after enrollment.

    Time frame: Baseline to 12 months (±2 months)

Secondary outcomes

  1. transient ischemic attack (TIA) or ischemic stroke in the qualifying artery territory within 1 year

    the number of participants who suffer from transient ischemic attack (TIA) or ischemic stroke in the qualifying artery territory within 1 year after enrollment.

    Time frame: Baseline to 12 months (±2 months)

  2. TIA related to ischemia in the qualifying artery territory within 1 year

    the number of participants who suffer from TIA related to ischemia in the qualifying artery territory within 1 year

    Time frame: Baseline to 12 months (±2 months)

  3. any stroke/TIA/ death within 1 year

    the number of participants who suffer from any stroke/TIA/ death within 1 year

    Time frame: Baseline to 12 months (±2 months)

  4. hemodynamic ischemic stroke in the qualifying artery territory within 1 year

    the number of participants who suffer from hemodynamic ischemic stroke in the qualifying artery territory within 1 year

    Time frame: Baseline to 12 months (±2 months)

  5. embolic stroke within in the qualifying artery territory 1 year

    the number of participants who suffer from embolic stroke within in the qualifying artery territory 1 year

    Time frame: Baseline to 12 months (±2 months)

07

Study locations

1 site
  • Department of Neurosurgery, Xuanwu hospital
    Beijing, Xicheng District 100053, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07309705
Lead sponsor
Xuanwu Hospital, Beijing
Collaborators
Suining Hospital of Traditional Chinese Medicine, Nanfang Hospital, Southern Medical University, The First Affiliated Hospital of Zhengzhou University, Xuanwu Jinan Hospital, The First Affiliated Hospital of University of Science and Technology of China, First Affiliated Hospital of Chongqing Medical University, Jiangmen Central Hospital, Hebi People's Hospital, Shanghai Sixth People's Hospital Anhui Branch
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Dec 1, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Dec 30, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion